BCG+MM

Non-muscle invasive bladder cancer is common and can cause substantial suffering. If the cancer is “high risk” then in over 30% of people it can turn into a more aggressive form of bladder cancer that requires treatment such as removal of or radiotherapy to the bladder within 5 years despite best current treatment. This risk can be reduced by placing BCG bacteria into the bladder. Recent preliminary studies show promising results from also placing mitomycin, a chemotherapy drug, into the bladder along with BCG treatment. This large-scale, randomised trial will determine the effects of adding mitomycin to BCG on cure rates, survival, side effects, and quality of life.